The src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells

Journal of Thoracic Oncology

Volumn 4, Issue 4, 2009, Pages 448-454

  Purnell, Phillip R ^a   Mack, Philip C ^a   Tepper, Clifford G ^a   Evans, Christopher P ^a   Green, Tim P ^b   Gumerlock, Paul H ^a   Lara, Primo N ^a   Gandara, David R ^a   Kung, Hsing Jien ^a   Gautschi, Oliver ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Invasion; Lung cancer; Metastasis; Protein kinase B; Signal transducer and activator of transcription; Src

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; FOCAL ADHESION KINASE; JANUS KINASE; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; 1,3 BENZODIOXOLE DERIVATIVE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; JAK3 PROTEIN, HUMAN; JANUS KINASE 3; MORPHOLINE DERIVATIVE; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 (2 (4 METHYLPIPERAZIN 1 YL)ETHOXY) 5 (TETRAHYDRO 2H PYRAN 4 YLOXY)QUINAZOLIN 4 AMINE; N-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-7-(2-(4-METHYLPIPERAZIN-1-YL)ETHOXY)-5-(TETRAHYDRO-2H-PYRAN-4-YLOXY)QUINAZOLIN-4-AMINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; QUINAZOLINE DERIVATIVE; RADIOSENSITIZING AGENT; STAT3 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CANCER INVASION; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; LUNG TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BENZODIOXOLES; CELL LINE, TUMOR; CELL MOVEMENT; CHROMONES; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; JANUS KINASE 3; LUNG NEOPLASMS; MORPHOLINES; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; STAT3 TRANSCRIPTION FACTOR;

EID: 67649396221     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31819c78fb     Document Type: Article

References (34)

1. Gautschi O, Gumerlock PH. Recent advances in the biology of lung cancer. In Hansen HH, (Ed.), Lung Cancer Therapy, Philadelphia, PA: Taylor & Francis Ltd., 2006.
2. Xi L, Coello MC, Litle VR, et al. A combination of molecular markers accurately detects lymph node metastasis in non-small cell lung cancer patients. Clin Cancer Res 2006;12:2484-2491.
3. Liu J, Blackhall F, Seiden-Long I, et al. Modeling of lung cancer by an orthotopically growing H460SM variant cell line reveals novel candidate genes for systemic metastasis. Oncogene 2004;23:6316-6324. (Pubitemid 39215302)
4. Parsons SJ, Parsons JT. Src family kinases, key regulators of signal transduction. Oncogene 2004;23:7906-7909.
5. Calalb MB, Polte TR, Hanks SK. Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol 1995;15:954-963.
6. Lu Y, Yu Q, Liu JH, et al. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 2003;278:40057-40066. (Pubitemid 37248572)
7. Cao X, Tay A, Guy GR, et al. Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol Cell Biol 1996;16:1595-1603. (Pubitemid 26095631)
8. Mazurenko NN, Kogan EA, Zborovskaya IB, et al. Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur J Cancer 1992;28:372-377.
9. Masaki T, Igarashi K, Tokuda M, et al. pp60c-src activation in lung adenocarcinoma. Eur J Cancer 2003;39:1447-1455.
10. Budde RJ, Ke S, Levin VA. Activity of pp60c-src in 60 different cell lines derived from human tumors. Cancer Biochem Biophys 1994;14:171-175.
11. Irby RB, Mao W, Coppola D, et al. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 1999;21:187-190. (Pubitemid 29070364)
12. Kiefer PE, Bepler G, Kubasch M, et al. Amplification and expression of protooncogenes in human small cell lung cancer cell lines. Cancer Res 1987;47:6236-6242. (Pubitemid 18011070)
13. Song L, Morris M, Bagui T, et al. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006;66:5542-5548. (Pubitemid 43927102)
14. Zhang J, Kalyankrishna S, Wislez M, et al. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 2007;170:366-376. (Pubitemid 47339214)
15. Lee D, Gautschi O. Clinical development of SRC tyrosine kinase inhibitors in lung cancer. Clin Lung Cancer 2006;7:381-384. (Pubitemid 44043546)
16. Johnson FM, Saigal B, Talpaz M, et al. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005;11:6924-6932. (Pubitemid 41428750)
17. Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007;67:2226-2238. (Pubitemid 46424242)
18. Serrels A, Macpherson IR, Evans TR, et al. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther 2006; 5:3014-3022. (Pubitemid 46092042)
19. Hiscox S, Morgan L, Green TP, et al. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006;97:263-274. (Pubitemid 43945756)
20. Phillips K, Parikh N, Kuwai T, et al. Inhibition of colon tumor metastasis in an orthotopic nude mouse model with the dual selective Src/Abl kinase inhibitor, AZD0530. J Clin Oncol (Meeting Abstracts) 2007;25:14032.
21. Chang YM, Bai L, Liu S, Yang JC, Kung HJ, Evans CP. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008;27:6365-6375.
22. Simon P. Q-Gene: processing quantitative real-time RT-PCR data. Bioinformatics 2003;19:1439-1440. (Pubitemid 36939825)
23. Blaskovich MA, Sun J, Cantor A, et al. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003;63: 1270-1279. (Pubitemid 36348705)
24. Hanke JH, Gardner JP, Dow RL, et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynTdependent T cell activation. J Biol Chem 1996;271:695-701. (Pubitemid 26034916)
25. Brognard J, Clark AS, Ni Y, et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001;61: 3986-3997. (Pubitemid 32720961)
26. Vlahos CJ, Matter WF, Hui KY, et al. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4- one (LY294002). J Biol Chem 1994;269:5241-5248. (Pubitemid 2045363)
27. Gautschi O, Tepper CG, Purnell PR, et al. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res 2008;68:2250-2258.
28. Haura EB. SRC and STAT pathways. J Thorac Oncol 2006;1:403-405.
29. Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003;22:4150-4165. (Pubitemid 36876236)
30. Gariboldi MB, Ravizza R, Molteni R, Osella D, Gabano E, Monti E. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett 2007;258:181-188. (Pubitemid 350101017)
31. Belyanskaya LL, Hopkins-Donaldson S, Kurtz S, et al. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer 2005;117:755-763. (Pubitemid 41598826)
32. Shah AN, Gallick GE. Src, chemoresistance and epithelial to mesenchymal transition: are they related? Anticancer Drugs 2007;18:371-375.
33. Griffiths GJ, Koh MY, Brunton VG, et al. Expression of kinasedefective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis. J Biol Chem 2004;279:46113-46121.
34. Contessa JN, Abell A, Mikkelsen RB, Valerie K, Schmidt-Ullrich RK. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation. Breast Cancer Res Treat 2006;95:17-27. (Pubitemid 43228078)